Legal Representation
Attorney
Carlynn Ferguson
USPTO Deadlines
Next Deadline
1568 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-10-24)
Due Date
October 24, 2029
Grace Period Ends
April 24, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
33 eventsDate | Code | Type | Description |
---|---|---|---|
Jun 5, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Jun 5, 2025 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
Jun 5, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Jun 5, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Feb 13, 2024 | NURC | C | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED |
Jan 5, 2024 | A7OK | O | AMENDMENT UNDER SECTION 7 - PROCESSED |
Jan 4, 2024 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED |
Nov 18, 2023 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
Oct 31, 2023 | ES7R | I | TEAS SECTION 7 REQUEST RECEIVED |
Oct 24, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
Oct 24, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Sep 20, 2023 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED |
Sep 20, 2023 | APET | A | ASSIGNED TO PETITION STAFF |
Aug 29, 2023 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED |
Aug 8, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Aug 8, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION |
Jul 19, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Jun 30, 2023 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE |
Jun 23, 2023 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
Jun 22, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jun 22, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
Jun 22, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Jun 22, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
Jun 22, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
May 20, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
May 19, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
May 19, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Feb 27, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Feb 27, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED |
Feb 27, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN |
Feb 16, 2023 | DOCK | D | ASSIGNED TO EXAMINER |
Oct 25, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Oct 13, 2022 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 001
Class 1: Chemical and biological preparations for use in science and industry; chemical and biological preparations for non-medical purposes; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; immunological agents and preparations for non-medical purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; nucleic recombinant acids; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
Class 005
Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely, for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely, stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; [ Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely, for medical conditions caused by the immune system; ] pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
Class 040
Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
Additional Information
Other
In the statement, line 39 through line 41, "Colostral antibodies for diagnostic, medical, therapeutic and prophylactic use, namely for medical conditions caused by the immune system;" is deleted.
Classification
International Classes
001
005
040